Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI

This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help in diagnosing patients correctly and may result in more timely treatment.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Heike E Daldrup-Link

Stanford Investigator(s):

Intervention(s):

  • Drug: Feraheme
  • Procedure: Magnetic Resonance Imaging (MRI) scan

Phase:

Phase 2

Eligibility


INCLUSION CRITERIA

   - Age 10 to 21 years

   - Suspected or confirmed diagnosis of a bone sarcoma or osteomyelitis

   - Informed consent with assent as appropriate.

EXCLUSION CRITERIA

   - Contraindication to MRI

   - Presence of metal implants

   - Need for sedation or anesthesia

   - Claustrophobia

   - Hemosiderosis or hemochromatosis

   - History of allergic reactions to similar compounds will be obtained and patients with
   positive history of allergic reactions will be excluded from the study

   - Females who are pregnancy or nursing

Ages Eligible for Study

10 Years - 21 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Anne Muehe
(650) 724-3191
Recruiting

Pediatric Trials